JP2023501386A5 - - Google Patents
Info
- Publication number
- JP2023501386A5 JP2023501386A5 JP2022526136A JP2022526136A JP2023501386A5 JP 2023501386 A5 JP2023501386 A5 JP 2023501386A5 JP 2022526136 A JP2022526136 A JP 2022526136A JP 2022526136 A JP2022526136 A JP 2022526136A JP 2023501386 A5 JP2023501386 A5 JP 2023501386A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- liver
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933277P | 2019-11-08 | 2019-11-08 | |
| US62/933,277 | 2019-11-08 | ||
| US202063004403P | 2020-04-02 | 2020-04-02 | |
| US63/004,403 | 2020-04-02 | ||
| PCT/US2020/059522 WO2021092474A1 (en) | 2019-11-08 | 2020-11-06 | Treating liver disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501386A JP2023501386A (ja) | 2023-01-18 |
| JP2023501386A5 true JP2023501386A5 (enExample) | 2023-11-13 |
Family
ID=75849579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526136A Pending JP2023501386A (ja) | 2019-11-08 | 2020-11-06 | 肝障害の治療 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4054567A4 (enExample) |
| JP (1) | JP2023501386A (enExample) |
| KR (1) | KR20220098168A (enExample) |
| CN (1) | CN114667142A (enExample) |
| AU (1) | AU2020380968A1 (enExample) |
| BR (1) | BR112022008639A2 (enExample) |
| CA (1) | CA3160445A1 (enExample) |
| CL (1) | CL2022001167A1 (enExample) |
| IL (1) | IL292459A (enExample) |
| MX (1) | MX2022005407A (enExample) |
| WO (1) | WO2021092474A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4259279A1 (en) | 2020-12-14 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors |
| TW202539702A (zh) * | 2024-03-08 | 2025-10-16 | 大陸商上海拓界生物醫藥科技有限公司 | 靶向ＩＮＨＢＥ的ＲＮＡｉ劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US20140187633A1 (en) * | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| MX2018011813A (es) * | 2016-03-28 | 2019-01-24 | Intercept Pharmaceuticals Inc | Medicina obtenida mediante la combinacion de agonista fxr y arb. |
| WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| US20210121493A1 (en) * | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| EP3844156A4 (en) * | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISEASES |
-
2020
- 2020-11-06 KR KR1020227018657A patent/KR20220098168A/ko not_active Withdrawn
- 2020-11-06 AU AU2020380968A patent/AU2020380968A1/en not_active Abandoned
- 2020-11-06 WO PCT/US2020/059522 patent/WO2021092474A1/en not_active Ceased
- 2020-11-06 CN CN202080077929.8A patent/CN114667142A/zh active Pending
- 2020-11-06 BR BR112022008639A patent/BR112022008639A2/pt not_active Application Discontinuation
- 2020-11-06 CA CA3160445A patent/CA3160445A1/en active Pending
- 2020-11-06 MX MX2022005407A patent/MX2022005407A/es unknown
- 2020-11-06 EP EP20886094.0A patent/EP4054567A4/en not_active Withdrawn
- 2020-11-06 JP JP2022526136A patent/JP2023501386A/ja active Pending
- 2020-11-06 IL IL292459A patent/IL292459A/en unknown
-
2022
- 2022-05-04 CL CL2022001167A patent/CL2022001167A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7313405B2 (ja) | 線維症の治療 | |
| JP2019511476A (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| US10980810B2 (en) | Combination therapy comprising an ACC inhibitor | |
| CN107106873A (zh) | 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 | |
| JP2019511478A (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| JP2023525571A5 (enExample) | ||
| EA038386B1 (ru) | Способы лечения холестатических заболеваний | |
| TW201735923A (zh) | 使用fxr促效劑之方法 | |
| JP2023500182A5 (enExample) | ||
| JP2022500366A (ja) | 肝疾患治療のための併用療法 | |
| IL291681B2 (en) | Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease | |
| AU2020201980A1 (en) | Combination of FXR agonists | |
| WO2019053582A1 (en) | COMBINATIONS HAVING FXR AGONISTS | |
| AU2017339826A1 (en) | Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder | |
| CA3144374A1 (en) | Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors | |
| Pass et al. | Current and emerging therapy for primary pulmonary hypertension | |
| JP2024520020A5 (enExample) | ||
| JP2023538065A5 (enExample) | ||
| JP2023501386A (ja) | 肝障害の治療 | |
| Halank et al. | Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan | |
| AU2019276955A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| Kapralou et al. | Metabolic effects of truncal vagotomy when combined with bariatric-metabolic surgery | |
| US20250332176A1 (en) | Treatment for fibrosis and inhibition of fibrosis | |
| RU2022104049A (ru) | Комбинированное лечение заболеваний печени агонистами fxr | |
| US6545044B2 (en) | Compositions of matter containing L-glutamine and pyridoxal-alpha-ketoglutarate |